BSE Pharma Sector Regulatory Filings — May 14, 2026
In the BSE PHARMA sector, Q4 FY26 earnings highlight robust growth led by Lupin with 32% YoY revenue and 68% EBITDA surge, contrasting Biocon's milder 10% revenue growth ex-one-time items, signaling US and biosimilars as key drivers amid mixed India performance. Aggregate revenue growth across reporting firms averages ~21% YoY in Q4 (Lupin 32%, Biocon 10%), with EBITDA margins expanding sharply (Lupin gross to 75% from 61.7% YoY, Biocon generics +300 bps QoQ). Aurobindo schedules earnings on May 22, 2026, kicking off catalyst season, while Sun Pharma's promoter reclassification of 1.80% shares to public could enhance free float. Sector themes include outperformance in US sales (Lupin +40% YoY) and biosimilars (Biocon +12% YoY), but CRDMO flatness at Biocon and modest India FY growth (Lupin +7.1%) flag domestic pressures. No capital allocation or insider trades noted beyond reclass, with forward pipelines (Lupin 50+ US launches) building multi-year alpha. Overall, mixed sentiment prevails, but Lupin emerges as top performer, warranting overweight amid earnings momentum.